Rigorous clinical research has led to the discovery of novel immunologic therapies. Chimeric antigen receptor T cell (CAR T-cell) therapy has shown impressive outcomes but is associated with a significant risk of adverse events (AEs), chiefly cytokine release syndrome (CRS). Bispecific antibodies act through a similar mechanism of action but offer a lower risk of CRS. These AEs may require immediate management, which may occur in the emergency department (ED) setting. Given the novelty and specialty nature of bispecific antibody and CAR T-cell therapies, ED clinicians face several challenges in the practical management of patients receiving these therapies. Similarly, given the breadth of conditions treated with these therapies, ED clinicians may face difficulties knowing which patient populations are at risk. While CAR T therapies are approved for hematologic malignancies, bispecific antibodies are approved for many indications including hematologic malignancies, non-small cell lung cancer, uveal melanoma, hemophilia A, and neovascular macular edema. This collaborative social learning platform establishes a network of providers who can create a sustainable network of providers who can continue to support each other following this experience in implementing their practice action plans aimed at improving the care provided to patients on CAR T or bispecific therapies.

CME/CE Accreditation Information

Endometrial cancer is among the few cancers increasing in incidence and mortality in the United States. In its early stages, endometrial carcinoma has a five-year relative survival rate of 96%, but it decreases to 18% for those with metastases. Surprisingly, mortality has been increasing faster than incidence. This is attributed to increasing rates of advanced cancers, higher-risk histologies, and older age of first diagnosis. Yet, there have also been increases in diagnoses in women aged less than 50 years, based on Surveillance, Epidemiology, and End Results (SEER) program data. While the incidence and mortality has been increasing across all racial groups, the rate of increase for Black women has been the steepest. Adjusting for the higher rate of hysterectomy in Black women compared with White women, the differing rates of this cancer in these groups exemplify this racial disparity. These statistics demonstrate the need for new therapeutics and subsequent education on their use in this field. To improve clinical outcomes, clinicians treating patients for advanced/recurrent endometrial cancer need to understand biomarker testing and molecular classification of disease, newest guidelines on management, and the evidence underlying these recommendations. Along with this, clinicians must be aware of the most effective ways to manage possible adverse events. To these ends, this educational initiative will allow clinicians managing patients with advanced/recurrent endometrial cancer to learn and discuss the crucial points in diagnosing and managing these patients to best increase long-term survival.

CME/CE Accreditation Information

Chronic kidney disease (CKD) is estimated to impact approximately 37 million individuals in the United States (U.S). Furthermore, about 786,000 persons are living with end-stage kidney disease (ESKD) and receive renal replacement therapy, either through maintenance dialysis or kidney transplantation. Hyperphosphatemia, characterized by phosphorus levels in the bloodstream exceeding the normal parameters of 2.5–4.5 mg/dL, constitutes a critical aspect of the mineral and bone disorder associated with CKD. Elevated levels of serum phosphorus facilitate vascular calcification, impair endothelial function, and may play a role in other newly identified mechanisms of cardiovascular toxicity specific to CKD. The treatment of hyperphosphatemia in patients with CKD requiring dialysis is complex and is ideally managed by a multidisciplinary team of care providers including nephrologists, advanced practice providers (APPs), nurses, dietitians, pharmacists, and other healthcare professionals. Evidence suggests that multidisciplinary care models can slow the progression of CKD and improve mortality rates, but gaps remain in the availability and implementation of these models across different healthcare settings. These challenges include dietary management, optimization of dialysis, pharmacological interventions, patient education, addressing adherence concerns, and the need for comprehensive care models. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with hyperphosphatemia.

CME/CE Accreditation Information

Immunotherapy, which has demonstrated benefits in advanced and metastatic settings, is moving into early non-small cell lung cancer treatment, expanding options for patients with resected or resectable early-stage non-small cell lung cancer. This rapid evolution of the early NSCLC treatment landscape, while exciting, has created clinical challenges as health care providers struggle with translating these clinical trial results into real-world clinical practices in the adjuvant and neoadjuvant settings. This educational initiative establishes impactful small group interactions among oncology care providers that will, through a variety of collaborative educational experiences, help them optimize the care of their patients with early-stage NSCLC.

CME/CE Accreditation Information

It is well recognized that early diagnosis and ongoing management of Alzheimer’s Disease (AD) requires a patient-centric, highly coordinated effort among a large multidisciplinary team of clinicians. As such, this proposed initiative establishes meaningful, small group interactions among key stakeholders (neurologists, dementia specialists, geriatricians, geriatric psychologists, radiologists, and primary care clinicians) that will, through a variety of collaborative educational experiences, help all members of the care team consider approaches to reducing barriers to effective coordinated care and encourages each participant to create an action plan to improve the quality of AD care delivered within their organization. Considering the complexity of this challenge, lack of expertise, and the breadth of communication and cooperation required, participants would highly benefit from an educational intervention that includes discussions with knowledgeable experts and peers from within and outside of their own communities who can share experiences, strategies, challenges, and success stories.

CME/CE Accreditation Information

The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.

CME/CE Accreditation Information

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries, with an age-adjusted incidence of 4.6 per 100,000 individuals per year. As small lymphocytic lymphoma (SLL) refers to the same malignant process with primary nodal involvement rather than blood, these are generally managed as a single condition (CLL/SLL). The selection of therapies for patients with relapsed/refractory CLL/SLL requires consideration of several factors including previous therapies, disease characteristics, and patient-specific factors such as co-morbidities and concurrent medications. Given the recency of new research into these targeted treatments and new approvals, clinicians lack background knowledge of the most current evidence and guideline recommendations in the treatment of CLL/SLL. Even within national guidelines, specific recommendations for initial treatment choice and sequencing are not directed. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL).

CME/CE Accreditation Information

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC). Prostate cancer is the most common solid cancer in men worldwide. Most men are diagnosed as having localized disease because of the widespread use of prostate-specific antigen screening. Men diagnosed as having clinically localized prostate cancer have multiple disease management options, including active surveillance, surgery, or radiotherapy. After local therapy, the treatment of early-stage non-metastatic biochemical recurrence (BCR) in hormone-sensitive (or castrate-sensitive) prostate cancer (HSPC) is not clear cut and options are limited. Treatment options also differ based on whether the patient has a low-risk or high-risk prostate cancer.

CME/CE Accreditation Information

This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, to learn and share best practices that will improve outcomes for patients with advanced and metastatic urothelial carcinoma. Advanced and metastatic urothelial carcinoma (a/mUC) of the bladder comprises a small subset of all urothelial tumors but accounts for the majority of the rapid mortality associated with this disease. Over the last decade, accelerating basic science research has enabled a deeper understanding of the molecular biology of urothelial tumors, leading to the development of novel treatment strategies. Immune checkpoint inhibitors (ICIs) have demonstrated encouraging results in the first-line and second-line treatment of mUC as well as in treatment-naïve cisplatin-ineligible patients with some durable responses and a favorable toxicity profile when compared to further chemotherapy. More recently, a new ICI/antibody-drug conjugate (ADC) combination has been approved. Given these changes, educational gaps exist for clinicians treating patients with advanced or metastatic UC in the areas of (1) determining cisplatin/platinum eligibility, (2) use of immuno-oncologic (IO) agents and IO/ADC combinations, and (3) managing adverse events associated with these treatments. This social learning experience will address these gaps and provide the opportunity to collaborate.

CME/CE Accreditation Information